ID-KORE-POWER/CLEANHILL
29.6.2021 14:02:12 CEST | Business Wire | Press release
KORE Power, Inc., (“KORE Power” or “KORE”) the leading U.S.-based developer of battery cell technology for the energy storage and electric transportation industries, announced that it has formed a strategic partnership with Cleanhill Partners (“Cleanhill”), a private equity firm pursuing investments in the energy transition sector that contribute to decarbonization. Cleanhill has invested in KORE Power as part of the strategic partnership.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629005233/en/
Rakesh Wilson and Ash Upadhyaya, founders of Cleanhill, have joined KORE Power as special advisors to Founder and CEO Lindsay Gorrill. As veterans of the energy finance and investment sector, Rakesh and Ash will guide KORE’s strategy on growth and investment opportunities.
“Rakesh and Ash bring over 40 years of combined experience in ESG, power, energy and infrastructure,” said CEO Lindsay Gorrill. “We are excited to partner with them to tap into their rich experience to position KORE as the leader in the energy transition sector.”
Ash Upadhyaya is a founder and Managing Partner at Cleanhill Partners. He has over 20 years of experience in private equity and engineering, focusing on the energy value chain. Ash was a Managing Director at Centerbridge Partners and a Director at KKR. He has engineering degrees from Stanford University and the University of Mumbai and an MBA from Stanford University.
“I’m thrilled to work with KORE Power to expand the design and manufacturing of lithium-ion battery cells in the U.S.,” said Ash. “Through my experience with energy storage, I see the critical role that batteries will play in the clean energy transition. I look forward to adding value to KORE’s expert team.”
Rakesh Wilson has over 20 years of energy finance and private equity experience and is a founder and Managing Partner at Cleanhill Partners. He previously served as a Senior Partner at Apollo Global Management and led private equity investments across the energy value chain. Rakesh was also with Morgan Stanley’s Commodities Division and Goldman Sachs’ investment banking and equity research divisions. He graduated from the University of Texas at Austin and received his MBA from INSEAD, Fontainebleau, France.
“Working with KORE Power is a natural extension of my work on battery storage projects, renewable infrastructure, distributed generation, energy trading funds and carbon offsets,” said Rakesh. “The lithium-ion cell is at the center of the clean energy future, and I look forward to accelerating the clean energy transition by working with KORE.”
Evercore served as financial advisor to KORE Power and Kirkland & Ellis LLP served as legal counsel to Cleanhill Partners.
ABOUT KORE Power
KORE Power, Inc., is a leading US-based developer of battery cell technology for the clean energy industry, serving energy storage, e-mobility, utility, industrial and mission-critical markets across the globe. KORE Power designs and manufactures its proprietary NMC and LFP cells, VDA modules and packs, optimized by the battery management system. Through its global partnerships, KORE designs and manufactures top-tier energy storage systems (ESS).
KORE Power’s differentiated approach provides customers with direct access, unparalleled service, superior technology, and Tier 1 product availability. We care about building sustainable communities, clean energy jobs and green economic expansion. KORE Power is proud to offer a functional solution to real-world problems that fulfill growing market demand and contribute to a zero-carbon future. For more information, visit www.korepower.com .
ABOUT Cleanhill Partners
Cleanhill Partners is a private equity firm pursuing investments in the energy transition sector that contribute to decarbonization. We invest in scalable businesses with visibility into revenues, earnings and cash flow growth. We leverage our thesis-driven approach and our operational expertise to enhance value in each of our investments. Our long-term investment philosophy to decarbonize and create value aligns our stakeholders, our communities and the businesses we invest in. The firm has offices in New York and Houston. To learn more, please visit www.cleanhillpartners.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005233/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom